Thrombolex, Inc. Secures $50 Million Series A Growth Financing to Advance Commercialization of its Innovative Pharmaco-Mechanical Lysis Technology (PML). Thrombolex, a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed, with strong support from current investors and co-founders.New Britain, PA March 16, 2026 --(PR.com)-- Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed, with strong support from current investors and co-founders.The financing strengthens the Company’s capital position as it expands U.S. commercial infrastructure and advances clinical evidence generation across its endovascular catheter platform.Thrombolex’s FDA cleared BASHIRTM Endovascular Catheter (BEC) systems are designed to enable rapid thrombus reduction using a single-session, on-the-table, ...Full story available on Benzinga.com
Read Full ArticleThis article was originally published on benzinga. Click the button above to read the complete article.
